# Review of OOD_ANON_37

**Manuscript Title:** [REDACTED FOR BLINDED REVIEW]  
**Authors:** [REDACTED FOR BLINDED REVIEW]  
**Journal / Preprint:** [REDACTED FOR BLINDED REVIEW]  
**Overall Score:** **3.8 / 10.0** (Flawed / Overstated)  
* **Score Breakdown:** Rigor: 1.0/3.5 | Claims: 0.9/2.5 | Biology: 0.9/2.0 | Reproducibility: 1.0/2.0

---

### 1. SUMMARY AND OVERALL IMPACT STATEMENT

This manuscript reports the synthesis and physicochemical characterization (FT-IR, UV-Vis, $^1\text{H}$/$^{13}\text{C}$ NMR, CW-EPR, TGA, PXRD, molar conductivity) of three salen-type Schiff base ligands—salophen (1), salen (2), and ethoxy-salen (3)—and their proposed octahedral diaqua copper(II) complexes, $[\text{Cu}^{\text{II}}(\text{L})(\text{H}_2\text{O})_2]$ (1–3). The authors combine Gaussian 09 DFT calculations, molecular docking against aromatase cytochrome P450 (`3eqm`) and CDK5 (`3ig7`), Deep-PK ADMET predictions, and in vitro cytotoxicity ($\text{IC}_{50}$) assays against MCF-7 breast cancer, HCT-116 colon cancer, and HFF-1 normal fibroblast cell lines, concluding that Complex 2 is the most potent and selective anticancer candidate. Supporting tables and spectra are included in the Supplementary Material.

The manuscript's primary conclusions are undermined by direct contradictions with its own experimental tables, unverified coordination stoichiometry, and inconsistencies across the computational and spectroscopic sections. First, the authors repeatedly claim (lines 96, 201, 257) that Complex 2 exhibits the lowest $\text{IC}_{50}$ against both MCF-7 and HCT-116 among all tested ligands and complexes; however, Table 4 shows that free Ligand 1 ($\text{IC}_{50} = 65.15\text{ }\mu\text{M}$) and free Ligand 3 ($\text{IC}_{50} = 169.0\text{ }\mu\text{M}$) are both substantially more potent against MCF-7 than Complex 2 ($\text{IC}_{50} = 212.5\text{ }\mu\text{M}$), and the free ligands were never tested on normal HFF-1 fibroblasts in Table 5. Second, the proposed six-coordinate diaqua formula $[\text{Cu}^{\text{II}}(\text{L})(\text{H}_2\text{O})_2]$ is not supported by elemental analysis (CHN), ESI-MS, or single-crystal XRD, and the TGA curves show no dehydration step below $283\text{--}306^\circ\text{C}$. Third, the docking section states that `AutoDock4` was used (line 48), whereas Table 2 reports `S` and `rmsd-Refine` columns characteristic of `MOE` without stating the DFT functional/basis set used in Gaussian 09. Substantial experimental verification of complex composition and a thorough revision of the biological and computational claims are required.

---

### 2. SPECIFIC CONCLUSIONS AND ASSESSMENT OF SUPPORT

* **Complex 2 exhibits the highest anticancer potency (lowest $\text{IC}_{50}$) against both MCF-7 and HCT-116 cells among all studied ligands and complexes, matching its top docking scores: [Methodologically Flawed].**  
  In Section 3 (line 96), Section 3.8 (line 201), and Section 3.10 (line 257), the authors state that Complex 2 has the best activity against both MCF-7 and HCT-116 across all compounds. In Table 4 (lines 270–275), however, Complex 2 has an $\text{IC}_{50}$ of $212.5 \pm 7.65\text{ }\mu\text{M}$ ($77.76\text{ }\mu\text{g mL}^{-1}$) against MCF-7, which is more than three times weaker than free Ligand 1 ($65.15 \pm 2.79\text{ }\mu\text{M}$, $20.61\text{ }\mu\text{g mL}^{-1}$) and also weaker than free Ligand 3 ($169.0 \pm 6.37\text{ }\mu\text{M}$, $60.25\text{ }\mu\text{g mL}^{-1}$). Furthermore, the docking rank order in Table 2—where Ligand 2 ($S = -8.65$ on `3eqm` and $-7.14$ on `3ig7`) scores much better than Ligand 1 ($-6.17$ and $-6.44$) and Ligand 3 ($-7.17$ and $-6.64$)—is the exact opposite of the experimental cytotoxicity rank order of the ligands in Table 4 ($\text{L1} > \text{L3} > \text{L2}$ in MCF-7; $\text{L3} > \text{L1} > \text{L2}$ in HCT-116).

* **Copper(II) complexes 1–3 are selective anticancer agents with a favorable therapeutic window compared to cisplatin (Table 5): [Overstated].**  
  With $\text{IC}_{50}$ values of $98.9\text{--}410.7\text{ }\mu\text{M}$ in cancer cells and $97.2\text{--}265.0\text{ }\mu\text{g mL}^{-1}$ in HFF-1 fibroblasts, Complexes 1–3 exhibit weak millimolar-to-high-micromolar nonspecific cytotoxicity ($5\text{--}20$-fold less potent than cisplatin) and modest selectivity indices ($\text{SI} = 1.25\text{--}2.69$). Moreover, Ligands 1–3 were omitted from the HFF-1 normal fibroblast assay in Table 5, so it is unknown whether metal complexation improves or degrades the selectivity of the parent ligands (especially Ligand 1, which had $\text{IC}_{50} = 65.15\text{ }\mu\text{M}$ in MCF-7).

* **Complexes 1–3 adopt six-coordinate octahedral $[\text{Cu}^{\text{II}}(\text{L})(\text{H}_2\text{O})_2]$ geometries confirmed by TGA, EPR, and DFT: [Fragile].**  
  No CHN elemental analysis, high-resolution mass spectrometry, or single-crystal X-ray structure is reported to establish the molecular formula. Usually, $\text{Cu(II)}$ salen/salophen complexes isolated from boiling ethanol crystallize as four-coordinate square-planar $[\text{Cu(L)}]$ or five-coordinate dimers rather than stable trans-diaqua octahedral monomers. In Section 3.5 (line 141), the first TGA mass loss does not begin until $283\text{--}306^\circ\text{C}$ and is assigned to simultaneous loss of $\text{C}_6\text{H}_{16}\text{N}_2\text{O}_3$ ($39.58\%$), $\text{C}_{10}\text{H}_{18}\text{N}_2\text{O}_3$ ($58.33\%$), or $\text{C}_{11}\text{H}_{19}\text{N}_2\text{O}_5$ ($57.12\%$) rather than a distinct loss of two coordinated $\text{H}_2\text{O}$ molecules ($36.03\text{ g mol}^{-1}$, $\sim 8\text{--}10\text{ wt}\%$) at $110\text{--}200^\circ\text{C}$. In Section 3.4 (line 128), the Hathaway parameter $G = (g_\parallel - 2.002)/(g_\perp - 2.002)$ is reported as $-1.25$ for Complex 3 (which would require $g_\parallel$ or $g_\perp < 2.002$, unphysical for $d^9$ $\text{Cu}^{\text{II}}$), and the text incorrectly states that $g_\parallel = g_\perp$ yields $G \approx 0$ instead of $G = 1$.

* **DFT frontier orbital parameters (Table 1) and AutoDock4 molecular docking scores (Table 2): [Methodologically Flawed].**  
  First, the Experimental and Computational sections (lines 43, 151) never specify the DFT exchange-correlation functional (e.g., B3LYP) or basis set (e.g., 6-31G(d)/LANL2DZ) used in Gaussian 09. Second, in Table 1, $E_{\text{LUMO}}$ for `L1` is printed as $+1.44\text{ eV}$ instead of $-1.44\text{ eV}$ (contradicting line 151 and the derived $\Delta E = 4.16\text{ eV}$ and $\chi = 3.52\text{ eV}$), the labels for global softness ($S = 1/2\eta$) and global electrophilicity ($\omega = \text{Pi}^2/2\eta$) are swapped in line 176, and $\Delta N_{\max}$ is given incorrect units of `$[eV]$` instead of being dimensionless. Third, while Section 2.4 (line 48) states docking was run in `AutoDock4`, Table 2 reports `S` and `rmsd-Refine`, which are outputs of the `MOE` docking suite, and line 228 assigns residue 437 of `3eqm` as both `Cys 437` and `Ala 437` in the same paragraph.

---

### 3. CONSTRUCTIVE AND DOABLE SUGGESTIONS FOR IMPROVEMENT

#### 1. Correct the MCF-7 Cytotoxicity Claims and Include Free Ligands in HFF-1 Selectivity Testing
* **WHY:** Table 4 shows that Ligand 1 ($\text{IC}_{50} = 65.15\text{ }\mu\text{M}$) and Ligand 3 ($\text{IC}_{50} = 169.0\text{ }\mu\text{M}$) are more active against MCF-7 than Complex 2 ($212.5\text{ }\mu\text{M}$), directly contradicting the claim that Complex 2 is the most potent compound across both cell lines.
* **WHAT:** Revise the Abstract, Section 3, Section 3.8, Section 3.10, and Conclusion to accurately state that Ligand 1 is the most potent compound in MCF-7 whereas Complex 2 is the most potent in HCT-116 ($98.91\text{ }\mu\text{M}$), and report HFF-1 $\text{IC}_{50}$ and Selectivity Index (SI) values for Ligands 1–3 in Table 5.
* **HOW:** Add the HFF-1 dose-response data for Ligands 1–3 to Table 5 and compute $\text{SI} = \text{IC}_{50}(\text{HFF-1}) / \text{IC}_{50}(\text{cancer})$ in both $\mu\text{g mL}^{-1}$ and $\mu\text{M}$.

#### 2. Provide Elemental Analysis / Mass Spectrometry and Re-Examine Axial Water Coordination
* **WHY:** Without CHN analysis or ESI-MS, and given the absence of any TGA mass loss below $283^\circ\text{C}$, the formulation of Complexes 1–3 as diaqua $[\text{Cu}(\text{L})(\text{H}_2\text{O})_2]$ rather than anhydrous four-coordinate $[\text{Cu}(\text{L})]$ is unsubstantiated, which also affects the molecular weights used to convert $\mu\text{g mL}^{-1}$ to $\mu\text{M}$ in Table 4.
* **WHAT:** Report CHN elemental analysis and/or ESI-MS for Ligands 1–3 and Complexes 1–3, and compare DFT geometry optimizations of four-coordinate square-planar $[\text{Cu}(\text{L})]$ vs. six-coordinate $[\text{Cu}(\text{L})(\text{H}_2\text{O})_2]$.
* **HOW:** Calculate the binding free energy of the two axial $\text{H}_2\text{O}$ ligands in Gaussian 09 (Typically elongated Jahn-Teller $\text{Cu–OH}_2$ bonds $> 2.4\text{ \AA}$ dissociate in solution and below $200^\circ\text{C}$ in TGA) and update the molecular weights in Table 4 if the bulk solids are anhydrous.

#### 3. Fully Document DFT Level of Theory and Reconcile Docking Software (`AutoDock4` vs. `MOE`)
* **WHY:** Omitting the DFT functional and basis set makes the quantum chemical calculations irreproducible, and reporting `MOE` output metrics (`S`, `rmsd-Refine`) under an `AutoDock4` methods description is a methodological contradiction.
* **WHAT:** State the exact DFT functional, basis set, spin multiplicity ($S = 1/2$, unrestricted Kohn-Sham UB3LYP/LANL2DZ or Def2-TZVP for $\text{Cu}^{\text{II}}$), and solvation model in Section 2.3/3.7, and clarify whether `MOE` or `AutoDock4` generated Table 2 and Figures 4–5.
* **HOW:** Add the Gaussian route card details to Section 3.7, specify the exact metal partial charges and force field used for $\text{Cu}^{\text{II}}$ during docking, and correct the `Cys 437` vs. `Ala 437` residue label error in line 228 (`Cys 437` is the proximal heme thiolate of CYP19A1 aromatase `3eqm`).

#### 4. Technical, Mathematical, and Editorial Cleanup
* **WHY:** Multiple sign errors, unit errors, and spectrometer frequency mismatches undermine technical credibility.
* **WHAT & HOW:**
  1. **Section 2.2 (line 38):** Reconcile `"1H NMR, 800 MHz and 13C NMR, 100 MHz on a Bruker Avance 800 MHz NMR"` ($100\text{ MHz}$ $^{13}\text{C}$ corresponds to a $400\text{ MHz}$ spectrometer; an $800\text{ MHz}$ spectrometer operates at $201\text{ MHz}$ for $^{13}\text{C}$).
  2. **Section 2.8 (line 72) & Section 3.4 (line 124):** Report the missing phenolic $-\text{OH}$ chemical shift for Ligand 2, change lowercase/uppercase `"S"` to `"s"` (singlet) and `"t"`/`"q"` for the ethoxy ethyl group in Ligand 3 (line 74, where $\text{CH}_3$ at $1.46\text{ ppm}$ and $\text{O–CH}_2$ at $4.12\text{ ppm}$ must be a triplet and quartet, not singlets!), and change `"C=NH"` to `"CH=N"` in line 124.
  3. **Section 3.2 (line 112):** Report molar conductivity $\Lambda_m$ in standard units ($\Omega^{-1}\text{ cm}^2\text{ mol}^{-1}$) rather than raw conductance ($\mu\text{S}$).
  4. **Section 3.4 (line 128):** Correct the statement `"G value close to 0 indicates an isotropic g-factor"` (when $g_\parallel = g_\perp$, $G = 1.0$) and check the $g_\parallel, g_\perp$ values in Table S4 that produced $G = -1.25$ for Complex 3.
  5. **Table 1 & Section 3.7 (lines 166–180):** Change `L1` $E_{\text{LUMO}}$ from `1.44` to `-1.44`, remove `$[eV]$` from the dimensionless $\Delta N_{\max}$ column header, and fix the swapped text definitions of $\omega$ (global electrophilicity index, in $\text{eV}$) and $S$ (global softness, in $\text{eV}^{-1}$).
